<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02688764</url>
  </required_header>
  <id_info>
    <org_study_id>PA-CL-PED-01</org_study_id>
    <nct_id>NCT02688764</nct_id>
  </id_info>
  <brief_title>An Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia</brief_title>
  <official_title>An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent CKD Patients With Hyperphosphataemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vifor Fresenius Medical Care Renal Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vifor Fresenius Medical Care Renal Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a Phase 3, Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Study
      to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in
      Paediatric and Adolescent CKD Patients with Hyperphosphataemia. The aim of this Phase 3
      clinical study is to demonstrate similar efficacy of PA21 (Velphoro) in paediatric and
      adolescent patients with CKD, and to provide safety and dosing information for this patient
      population. The Phoslyra (comparator) group provides information for a descriptive comparison
      of PA21 against a commonly used calcium-based phosphate binder (calcium acetate).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum phosphorus from baseline in the PA21 group</measure>
    <time_frame>At the end of Stage 1 (up to 10 weeks after randomization)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum phosphorus from baseline in the Phoslyra group</measure>
    <time_frame>At end of Stage 1 (up to 10 weeks after randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum phosphorus from baseline in the PA21 group</measure>
    <time_frame>through study completion, an average of 34 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum phosphorus from baseline in the Phoslyra group</measure>
    <time_frame>through study completion, an average of 34 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects in each stage during which the subject has serum phosphorus levels in the age dependent target ranges.</measure>
    <time_frame>through study completion, an average of 34 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Hyperphosphatemia</condition>
  <arm_group>
    <arm_group_label>PA21 (Velphoro®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PA21 (Velphoro®), chewable tablets 500 mg iron
PA21 (Velphoro®), chewable tablets 250 mg iron
PA21 (Velphoro®), powder for oral suspension 500 mg iron
PA21 (Velphoro®), powder for oral suspension 250 mg iron
PA21 (Velphoro®), powder for oral suspension 125 mg iron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium Acetate (Phoslyra®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcium Acetate (Phoslyra®) - Oral Solution: 667 mg calcium acetate per 5 mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PA21 (Velphoro®)</intervention_name>
    <description>During Stage 1 (Open-Label Dose Titration; up to 10 weeks), PA21 subjects will receive PA21 at a starting dose based on their age. Dose of PA21 will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.
During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2.</description>
    <arm_group_label>PA21 (Velphoro®)</arm_group_label>
    <other_name>sucroferric oxyhydroxide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Acetate (Phoslyra®)</intervention_name>
    <description>During Stage 1 (Open-Label Dose Titration; up to 10 weeks), Phoslyra subjects will receive Phoslyra either at a starting dose based on their weight or, if considered more appropriate by the Investigator, at an equivalent dose of their previous phosphate binder (PB), calcium-based or sevelamer. Dose of Phoslyra will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.
During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2.</description>
    <arm_group_label>Calcium Acetate (Phoslyra®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects 0 to &lt;18 years at time of consent.

          2. Subjects with hyperphosphataemia

          3. Subjects ≥1 year with CKD Stages 4-5 defined by a glomerular filtration rate &lt;30
             mL/min/1.73 m2 or with CKD Stage 5D receiving adequate maintenance haemodialysis (HD)
             or peritoneal dialysis (PD) for at least 2 months prior to screening.

          4. Subjects &lt;1 year must have CKD.

          5. Appropriate written informed consent and, where appropriate/required assent, have been
             provided.

        Exclusion Criteria:

          1. Subjects with hypercalcaemia at screening

          2. Subjects with intact parathyroid hormone (iPTH) levels &gt;700 pg/mL at screening.

          3. Subjects who are PB naïve who weigh &lt;5 kg at screening. Subjects receiving stable
             doses of PBs who weigh &lt;6 kg at screening

          4. Subjects requiring feeding tube sizes ≤6 FR (French catheter scale).

          5. Subjects with history of major gastrointestinal surgery or significant
             gastrointestinal disorders.

          6. Subjects with hypocalcaemia (serum total corrected calcium &lt;1.9 mmol/L; &lt;7.6 mg/dL) at
             screening.

          7. Subject is pregnant (e.g., positive human chorionic gonadotropin test) or breast
             feeding.

          8. Subject has a significant medical condition(s)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry A Greenbaum, MD; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Healthcare of Atlanta at Egleston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sven Knapinski, PhD</last_name>
    <phone>+41588518261</phone>
    <email>Sven.Knapinski@viforpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham School of Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sahar Fathallah-Shaykh, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun Young Ahn</last_name>
    </contact>
    <investigator>
      <last_name>Sun Young Ahn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami - Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Abitbol</last_name>
    </contact>
    <investigator>
      <last_name>Caroline Abitbol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Paredes</last_name>
    </contact>
    <investigator>
      <last_name>Ana Paredes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Mathias</last_name>
    </contact>
    <investigator>
      <last_name>Robert Mathias</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory-Children's Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322-1014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Larry A. Greenbaum, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Misurac</last_name>
    </contact>
    <investigator>
      <last_name>Jason Misurac</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larysa Wickman</last_name>
    </contact>
    <investigator>
      <last_name>Larysa Wickman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keith Hruska, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Keith Hruska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601-1914</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Lieberman</last_name>
    </contact>
    <investigator>
      <last_name>Kenneth Lieberman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Barnabas Medical Center</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039-5672</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shefali Vyas</last_name>
    </contact>
    <investigator>
      <last_name>Shefali Vyas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Wong</last_name>
    </contact>
    <investigator>
      <last_name>Craig Wong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Perelstein</last_name>
    </contact>
    <investigator>
      <last_name>Eduardo Perelstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shashi Nagaraj</last_name>
    </contact>
    <investigator>
      <last_name>Shashi Nagaraj</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale Lane</last_name>
    </contact>
    <investigator>
      <last_name>Pascale Lane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University, Doernbecher Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amira Al-Uzri</last_name>
    </contact>
    <investigator>
      <last_name>Amira Al-Uzri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Laskin</last_name>
    </contact>
    <investigator>
      <last_name>Benjamin Laskin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mouin Seikaly</last_name>
    </contact>
    <investigator>
      <last_name>Mouin Seikaly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital - Texas Children's Feigin Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Swartz</last_name>
    </contact>
    <investigator>
      <last_name>Sarah Swartz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Medical School at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Swinford</last_name>
    </contact>
    <investigator>
      <last_name>Rita Swinford</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raoul Nelson</last_name>
    </contact>
    <investigator>
      <last_name>Raoul Nelson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajasree Sreedharan</last_name>
    </contact>
    <investigator>
      <last_name>Rajasree Sreedharan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Lahoche</last_name>
    </contact>
    <investigator>
      <last_name>Annie Lahoche</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu de Lyon - Hopital Femme Mere Enfant</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Ranchin</last_name>
    </contact>
    <investigator>
      <last_name>Bruno Ranchin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie et Endocrinologie pédiatriques</name>
      <address>
        <city>Montpellier cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Fila</last_name>
    </contact>
    <investigator>
      <last_name>Marc Fila</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Galiano</last_name>
    </contact>
    <investigator>
      <last_name>Matthias Galiano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg GmbH</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikola Jeck</last_name>
    </contact>
    <investigator>
      <last_name>Nikola Jeck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Of Lithuanian University Of Health Sciences Kaunas Clinics</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jurate Masalskiene</last_name>
    </contact>
    <investigator>
      <last_name>Jurate Masalskiene</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Affiliate of Vilnius University Hospital Santariskiu Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>8406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Augustina Jankauskiene</last_name>
    </contact>
    <investigator>
      <last_name>Augustina Jankauskiene</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Dziecięcy Szpital Kliniczny im. L. Zamenhofa w Białymstoku</name>
      <address>
        <city>Białystok</city>
        <zip>15-274</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Wasilewska</last_name>
    </contact>
    <investigator>
      <last_name>Anna Wasilewska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandra Zurowska</last_name>
    </contact>
    <investigator>
      <last_name>Aleksandra Zurowska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Dzieciecy w Krakowie - Prokocimiu</name>
      <address>
        <city>Krakow</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorota Drozdz</last_name>
    </contact>
    <investigator>
      <last_name>Dorota Drozdz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instytut &quot;Pomnik - Centrum Zdrowia Dziecka&quot;</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylwester Prokurat</last_name>
    </contact>
    <investigator>
      <last_name>Sylwester Prokurat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenţă pentru copii &quot;Maria Sklodowska Curie&quot;</name>
      <address>
        <city>Bucureşti</city>
        <state>Bucharest</state>
        <zip>077120</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mihaela Bălgrădean</last_name>
    </contact>
    <investigator>
      <last_name>Mihaela Bălgrădean</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Fundeni Bucureşti</name>
      <address>
        <city>București</city>
        <state>Bucharest</state>
        <zip>22322</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Stoica</last_name>
    </contact>
    <investigator>
      <last_name>Cristina Stoica</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2016</study_first_submitted>
  <study_first_submitted_qc>February 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2016</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PA21</keyword>
  <keyword>phosphate binder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcium acetate</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

